Skip to content

Effects of Viral Reactivation on Outcomes of Brain-injured Patients ( IBIS-VIRUS)

Effects of Viral Reactivation on Outcomes of Brain-injured Patients ( IBIS-VIRUS)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02003196
Acronym
IBIS-VIRUS
Enrollment
375
Registered
2013-12-06
Start date
2014-01-05
Completion date
2020-03-26
Last updated
2021-08-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain Injury

Keywords

Brain injury, virus, immunosuppression, mechanical ventilation

Brief summary

Morbidity and mortality of ICU patients is increased by the development of a immunosuppression systemic (IS). This IS develops in the early hours of hospitalization and is responsible for severe infections, including viral reactivations (Cytomegalovirus or Herpes Simplex Virus). Viral reactivation was associated with increased morbidity and mortality in intensive care units. In clinical practice, they are searched at the onset of organ failure or unexplained fever. The investigators wish to conduct this research in the stroke patients to assess the predictive power of these viral reactivations on the duration of mechanical ventilation.

Detailed description

PCR for herpes simplex virus in blood and in tracheal aspirate (Day-1, Day-7 and Day-15) - clinicians are blinded to the results PCR for Cytomegalovirus in blood and in tracheal aspirate (Day-1, Day-7 and Day-15) - clinicians are blinded to the results

Interventions

None listed

Sponsors

Nantes University Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Hospitalisation in intensive care unit * Acute brain injury (trauma, subarachnoid haemorrhage, stroke, infection) with Glasgow Coma Scale \<= 12 * Age between 18 and 75 years * Mechanical ventilation \> 24 hours

Exclusion criteria

* encephalopathy post anoxy * active cancer * Immunosuppresseur treatment * pregnancy * history of autoimmune disease

Design outcomes

Primary

MeasureTime frame
Ventilatory-free days at day 9090 days

Secondary

MeasureTime frame
Bacterial hospital acquiered infection28 days
organ failure28 days
hospitalisation length of stay28 days
Mortality28 days and 90 days

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 14, 2026